Stockreport

Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Seres Therapeutics, Inc.  (MCRB) 
Last seres therapeutics, inc. earnings: 11/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.serestherapeutics.com
PDF – Company anticipates reporting initial SER-155 safety and pharmacological data from study Cohort 1 in the coming months – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Th [Read more]